-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
I-Mab, a clinical biopharmaceutical company dedicated to the discovery and development of new biologics, announced today that its proprietary CD73 antibody uliledlimab (also known as TJD5, or TJ004309) has made progress in several clinical trials in China and the United States.
plans to present detailed clinical results at some scientific conferences this year.
CD73 is associated with tumor resistance to checkpoint immunotherapy, as CD73 played a key role in adenosine-mediated tumor microeconductive immunosuppression.
Uliledlimab is a humanized anti-CD73 antibody that effectively regulates the tumor micro-environment by inhibiting adenosine.
preclinical studies have shown that Uliledlimab strongly inhibits tumor growth, especially when used in association with PD-(L)1 inhibitors.
anti-CD73 antibody, Uliledlimab interacts with a unique mesolymer binding pattern with a unique mesolymer.
of preclinical and pathological studies have been presented to the upcoming annual meeting of the American Association for Cancer Research.
significant progress has been made in the global clinical development of Uliledlimab.
in China, I-Mab is advancing the treatment of patients with advanced or metastasis cancers with difficulty or poor tolerance for Uliledlimab monodratives or in a joint treatment with Tolipa monotherapy (TUOYI®).
